NovaBridge Biosciences (FRA:0VY) General and Admin. Expense: €27.14 Mil (TTM As of Dec. 2025)


FRA:0VY NovaBridge Biosciences FRA:0VY
23 GF Score
Price €1.66
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences General and Admin. Expense?

NovaBridge Biosciences FRA:0VY -4.60% 23 General and Admin. Expense is €27.14 Mil as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. NovaBridge Biosciences's General and Admin. Expense for the three months ended in Dec. 2025 was €14.73 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €27.14 Mil.

NovaBridge Biosciences General and Admin. Expense Related Terms

NovaBridge Biosciences General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences General and Admin. Expense Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only 124.95 27.36 25.82 28.32 26.79

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.01 4.15 3.31 4.95 14.73
FRA:0VY
23GF Score
NovaBridge Biosciences FRA:0VY
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €27.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €27.14 Mil mean?
NovaBridge Biosciences (FRA:0VY) has a General and Admin. Expense of €27.14 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' General and Admin. Expense too high?
NovaBridge Biosciences' current General and Admin. Expense is €27.14 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' General and Admin. Expense compare to HUMA and DTIL?
NovaBridge Biosciences' General and Admin. Expense of €27.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current General and Admin. Expense is €27.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (FRA:0VY) has a current General and Admin. Expense of €27.14 Mil. The current General and Admin. Expense is €27.14 Mil. NovaBridge Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current General and Admin. Expense is €27.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
23GF Score

Get the complete analysis for FRA:0VY

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66
Price